The advent of CRISPR & genome editing technologies has ushered in a new era of genetic precision, enabling targeted modifications with unprecedented accuracy. CRISPR-Cas systems allow scientists to cut, delete, or replace DNA sequences in a wide range of organisms, offering therapeutic possibilities for genetic diseases, cancer, and infectious conditions. Beyond CRISPR, novel editing tools like base editors and prime editors are expanding the genome editing toolkit. Researchers are now combining CRISPR & Genome Editing Technologies with delivery platforms such as viral vectors and nanoparticles to improve efficiency and specificity. These tools are also critical for functional genomics, crop enhancement, and synthetic biology. As ethical and regulatory frameworks evolve, genome editing remains one of the most transformative technologies in modern biotechnology.
Title : Biotech innovations: Bioengineering potential for novel biomanufacturing systems
Murray Moo Young, University of Waterloo, Canada
Title : Targeting noncanonical epitopes in anti-cancer immunotherapy
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Stem cell therapy: An affordable healthcare therapy for various diseases
Anant Marathe, Total Potential Cells (P) Ltd, India
Title : Eliminating implant infection: 30,000 nanotextured implants in humans with no failure
Thomas J Webster, Interstellar Therapeutics, United States
Title : Development and characterization of exo-ITC: A fibrous bilayer exosome delivery system for dermatological applications
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Information leakage: Types, remedies, and open problems
Julia Sidorova, Centro de Investigación Biomédica En Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain